Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer
NCT01047891
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
174
Enrollment
OTHER
Sponsor class
Conditions
Ovarian Cancer
Interventions
DRUG:
Sorafenib
Sponsor
JSehouli